Literature DB >> 10542444

Molecular pharmacology of the CFTR Cl- channel.

T C Hwang1, D N Sheppard.   

Abstract

Dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is associated with a wide spectrum of disease. In the search for modulators of CFTR, pharmacological agents that interact directly with the CFTR Cl- channel have been identified. Some agents stimulate CFTR by interacting with the nucleotide-binding domains that control channel gating, whereas others inhibit CFTR by binding within the channel pore and preventing Cl- permeation. Knowledge of the molecular pharmacology of CFTR might lead to new treatments for diseases caused by the dysfunction of CFTR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542444     DOI: 10.1016/s0165-6147(99)01386-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  49 in total

1.  Molecular determinants of Au(CN)(2)(-) binding and permeability within the cystic fibrosis transmembrane conductance regulator Cl(-) channel pore.

Authors:  Xiandi Gong; Susan M Burbridge; Elizabeth A Cowley; Paul Linsdell
Journal:  J Physiol       Date:  2002-04-01       Impact factor: 5.182

2.  Alternating access to the transmembrane domain of the ATP-binding cassette protein cystic fibrosis transmembrane conductance regulator (ABCC7).

Authors:  Wuyang Wang; Paul Linsdell
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

3.  Interaction non grata between CFTR's correctors and potentiators.

Authors:  Wen-Ying Lin; Ying-Chun Yu
Journal:  Ann Transl Med       Date:  2015-04

4.  CFTR and calcium-activated chloride channels in primary cultures of human airway gland cells of serous or mucous phenotype.

Authors:  Horst Fischer; Beate Illek; Lorne Sachs; Walter E Finkbeiner; Jonathan H Widdicombe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-07-30       Impact factor: 5.464

5.  Mechanism of lonidamine inhibition of the CFTR chloride channel.

Authors:  Xiandi Gong; Susan M Burbridge; Angie C Lewis; Patrick Y D Wong; Paul Linsdell
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

6.  Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Authors:  Puay-Wah Phuan; Jung-Ho Son; Joseph-Anthony Tan; Clarabella Li; Ilaria Musante; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Mark J Kurth; Luis J Galietta; Peter M Haggie; Alan S Verkman
Journal:  J Cyst Fibros       Date:  2018-06-12       Impact factor: 5.482

7.  Direct effects of 9-anthracene compounds on cystic fibrosis transmembrane conductance regulator gating.

Authors:  Tomohiko Ai; Silvia G Bompadre; Yoshiro Sohma; Xiaohui Wang; Min Li; Tzyh-Chang Hwang
Journal:  Pflugers Arch       Date:  2004-10       Impact factor: 3.657

8.  On the mechanism of CFTR inhibition by a thiazolidinone derivative.

Authors:  Zoia Kopeikin; Yoshiro Sohma; Min Li; Tzyh-Chang Hwang
Journal:  J Gen Physiol       Date:  2010-11-15       Impact factor: 4.086

9.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.

Authors:  Kang-Yang Jih; Tzyh-Chang Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

10.  CFTR directly mediates nucleotide-regulated glutathione flux.

Authors:  Ilana Kogan; Mohabir Ramjeesingh; Canhui Li; Jackie F Kidd; Yanchun Wang; Elaine M Leslie; Susan P C Cole; Christine E Bear
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.